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Abstract
Objectives: Hearts preserved ex vivo at 4°C undergo time-dependent irreversible injury due to extreme
hypothermia. Studies using novel organ preservative solution SOMAH, suggest that hearts are optimally
‘preserved’ at subnormothermic temperature of 21°C. Present study evaluates relative efficacy of SOMAH
‘cardioplegia’ at 4 and 21°C in preservation of optimum heart function after in vitro storage at subnormothermia.
Methods: Porcine hearts arrested with SOMAH cardioplegia at 4 or 21°C were stored in SOMAH for 5-hour at 21°C
(n= 5). At the end of storage, the weight of hearts was recorded and biopsies taken for cardiac tissue high energy
phosphate level measurements. The hearts were then attached to a reperfusion apparatus and biochemical
parameters including cardiac enzyme release and myocardial oxygen consumption and lactate production were
determined in perfusate samples at regular intervals during ex vivo perfusion experiment. Functional evaluation
of the hearts intraoperatively and ex vivo was performed by 2D echocardiography using trans-esophageal
echocardiography probe.
Results: Post-storage heart weights were unaltered in both groups, while available high-energy phosphates (HEP)
were greater in the 21°C group. Upon ex vivo reperfusion, coronary flow was significantly greater (p < 0.05) in 21°C
group. 2D echo revealed a greater cardiac output, fractional area change and ejection fraction in 21°C group that
was not significantly different than the 4°C group. However, unlike 4°C hearts, 21°C hearts did not require inotropic
intervention. Upon reperfusion, rate of cardiac enzyme release temporally resolved in 21°C group, but not in the
4°C group. 21°C working hearts maintained their energy state during the experimental duration but not the 4°C
group; albeit, both groups demonstrated robust metabolism and function during this period.
Conclusions: Rapid metabolic switch, increased synthesis of HEP, decreased injury and optimal function provides
evidence that hearts arrested at 21°C remain viably and functionally superior to those arrested at 4°C when stored
in SOMAH at ambient temperature pre-transplant.
Ultramini-abstract: Cardioplegic arrest and preservation of hearts in SOMAH at ambient temperature efficiently
conserves metabolism and function in in vitro porcine model of heart transplant.
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Cardioplegia, a technique to stop the heart intraopera-
tively, is an integral part of open-heart surgeries and is
also a fundamental requisite in the field of heart trans-
plant. During surgery it is important for cardioplegia
solution to not only arrest the heart adequately but also
prevent damage to cardiac tissue during and/or after infu-
sion. Several strategies to attain this ideal situation have
been attempted by altering cardioplegia temperature, or
using blood, crystalloid or blood-crystalloid mixture that
have produced equivocal results in their ability to arrest
the heart [1-6]. However, the meta-analysis of these stud-
ies does not provide much evidence in favor of one or the
other [7,8]. Nevertheless, of all these strategies by far, the
use of high K
+ cardioplegia at extreme hypothermia
(4°C) has become most widely accepted, especially in
the procurement of donor hearts for transplant [9].
This is despite the growing awareness of the damaging
effects of extreme hypothermia on solid organs [10,11]
and failure of presently used modalities in extracorporeal
preservation of hearts to extend the ex vivo storage time
beyond 4–6h o u r s .
Recent results from our laboratory using animal models
of heart transplant have demonstrated that hearts pre-
served in SOMAH solution of our design, demonstrate
greater accumulation of high energy phosphates (HEP) in
comparison to the comparator solutions [12-16]. Further-
more, hearts preserved in SOMAH for 5–24 hours and
not exposed to extreme hypothermia (4°C) demonstrate a
robust maintenance of organ viability and function, and
minimal injury upon reperfusion and reanimation [12-14].
Additionally, these studies also demonstrate that hearts
stored in SOMAH at 21°C outperform those preserved at
4 and 13°C upon reanimation. However, in these investiga-
tions SOMAH cardioplegia was delivered at 4°C for arrest
prior to excision of donor hearts. Since preservation of
hearts in SOMAH at 21°C was superior than that at 4°C,
the present study was undertaken to assess whether deliv-
ery of high K
+ SOMAH cardioplegia at 21°C compared to
that at 4°C would further augment and improve viability
and energy metabolism, and also prevent injury in hearts
stored ex vivo for 5 hours at 21°C, that were then reper-
fused and reanimated for evaluation of cardiac function.
Methods
Animal protocol
Heart procurement surgery and cardioplegia
Ten female Yorkshire swine (45–54 Kg) were used in
this comparative study. Hearts were divided into two
groups of either 4°C (n =5) or 21°C cardioplegia (n = 5),
as per the protocol approved by our Animal Studies
Committee (Institutional Animal Care and Use Commit-
tee). Hearts were extracted using mediastinal approach as
described [12]. The animals were bled from femoral vessels
to collect blood for ex vivo experiments, and aorta was
clamped when systolic pressure fell below 40 mmHg.
1000 ml of SOMAH cardioplegia (SOMAH [12] modified
by addition of 20 mM K
+, final concentration), at 4 or 21°C
was infused into the aortic root at a pressure of 75–
100 mmHg at a flow rate of 300–400 ml/minute using
roller pump and pressure transducer (Myotherm Cardio-
plegia System, Medtronics, Minneapolis, MN, USA) and
the data was recorded using iWorks system (Dover, NH,
USA). After cardioplegic arrest, heart was dissected from
all attachments and rinsed with normal saline before
storing in SOMAH for 5-hours at 21°C. Hearts were trans-
ported to the lab within 15 minutes of excision.
Extracorporeal storage of heart
Hearts were placed in sterile zip-lock bags containing 2 L
of SOMAH in water-jacketed water bath at 21±2°C. The
temperature of preservation solution was checked regu-
larly during the entire storage period. Hearts were main-
tained in a non-contractile state by increasing SOMAH’s
plegia potential by supplementing the solution with
20 mM K
+ complemented by 37 mM Mg
2+ [17,18], during
storage. Hearts in each group were weighed prior to and
after 5-hour storage upon carefully emptying the heart
chambers. Tissue punch biopsies (2X4 mm) were taken in
the lab from the posterior wall of LV, 15 minutes into
(0 hour; control) and after 5 hour storage for HEP assays.
ATP and creatine phosphate assay
ATP and creatine phosphate (CP) were measured in tis-
sue extracts as described [12,19]. In brief, tissue biopsies
were flash frozen and stored at −80°C; 20 mg of tissue
was suspended in 400 μl of 0.4 M ice-cold perchloric
acid and homogenized twice for 30 seconds. Homogen-
ate was centrifuged at 1970 g for 10 minutes at 0°C. An
aliquot of supernatant was neutralized with equal volume
of ice-cold 0.4 M KHCO3 and centrifuged as above. The
supernatant was stored at −80°C for ATP and CP mea-
surements. The pellet was dissolved in equal volume of
0.1 M NaOH, centrifuged and used for protein assay.
ATP and CP were measured using a bioluminescent
assay kit (Sigma-Aldrich and GloMax-Multi+Detection
System, Promega), according to the protocol provided by
the manufacturer.
Preparation of heart for ex vivo resuscitation and
functional studies
Aorta and pulmonary artery (PA) were separated. Aorta
was cannulated (1/2-3/8 inch tubing connector) and cor-
onaries were gently flushed with 100 ml of SOMAH in
both 4°C and 21°C cardioplegia groups at 40–50 mmHg
pressure, carefully avoiding entry of air into the aorta.
Pulmonary veins (PV) were separated and cannulated
with 1/2-1/4 inch tubing connector. PA was cannulated
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cavas were ligated.
Preparation of blood for ex vivo studies
Systemically heparinized blood was collected intraopera-
tively, leukodepleted (Pall Leukoguard filter) and stored
at 4°C. Prior to experiments, perfusate was prepared by
adjusting the hematocrit of blood to 20% using SOMAH
solution (1:1 ratio to reduce viscous strain on heart) and
warmed to 21°C. The perfusate, pH, glucose, K
+,C a
2+
and HCO
3− were adjusted for swine blood levels (7.5;
100 mg/dl; 3.7, 1.38, and 32 mmol/l respectively), using
10% dextrose, KCl, CaCl2 and NaHCO3, respectively, as
required.
The SOMAH device
A custom-built apparatus was used for extra-corporeal
reanimation of hearts (Figure 1, Additional file 1: Video).
CDI monitor (Clinical Documentation Improvement
monitoring system 500, Terumo cardiovascular systems
corporation, Ann Arbor, MI), was used for real-time
monitoring of perfusate pH, temperature, pO2, pCO2,K
+
and HCO3
−. These parameters were also analyzed in in-
flow/outflow samples using i-STAT analyzer (Abaxis Ltd,
Union city, CA). Pressures and flows were recorded at
various points in the circuits (Figure 2). A trans-esophageal
echocardiography (TEE) probe was used to assess the
contractile function of heart using the 2D-Echo sys-
tem. 3-lead ECG was recorded during 2D Echo using
brass crocodile leads immersed in the perfusate surround-
ing the heart. Pressures and flow data was acquired and
monitored in real time using HMI software, specifically
written for SOMAH Device (Comdel Inc, Wahpeton, ND).
Ex vivo functional studies
Hearts were attached to SOMAH Device and perfused
through the aorta at 40–60 mmHg for 5 minutes, with
1–1.5 liters of SOMAH at 21°C (pH 7.5), and then with
perfusate, till pH, blood gases and electrolyte equilibrium
was established. The perfusate pH, glucose, K
+,C a
2+,
HCO
3− were adjusted for swine blood levels as mentioned
above. Strong cardiac contractions were noted in both
groups as the system temperature was gradually raised to
37°C over a 30 minute period. Hemodynamic steady state
(with respect to pH, blood gases, and electrolytes) was
achieved within 40 minutes. Total duration of the experi-
mental perfusion was approximately 180 minutes. Hearts
were perfused through aortic root (no workload) until the
system temperature reached 37°C, after which PV perfu-
sion (full workload) proceeded until end of experiment.
Coronary blood flow was determined during the initial
antegrade perfusion by the amount of perfusate flowing to
Figure 1 Circuit diagram of the SOMAH Device. A custom-built apparatus was designed for extra-corporeal reanimation of hearts. The circuit 1
(green) visualizes antegrade coronary perfusion through aorta during initial reperfusion of hearts and circuit 2 (red), for perfusion of hearts
through PV in the working state. In circuit 1, the perfusate is pumped from heart chamber to oxygenator-heat-exchanger system and eventually
into aorta for coronary perfusion. The return of perfusate to heart chamber through PA completes the circuit. In circuit 2, blood pumped from
heart to oxygenator-heat-exchanger system is collected in pre-load bag from where it drained into the PV by gravity. The pressures/flows are
adjusted by altering the height of pre-load bag. This circuit is diverted into two components. First component is the part of perfusate that enters
coronaries and returns to heart chamber through PA. The second component is formed by the perfusate that continues through aorta into the
after-load chamber, from where the perfusate returns to heart chamber by gravity. A CDI monitor was incorporated beyond oxygenator-heat-exchanger
system for real-time monitoring of perfusate pH, temperature, pO2,p C O 2,K
+ and HCO
3−. Pressures and flows were recorded at various points in the two
circuits and monitored using HMI software specifically written for SOMAH Device.
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heart by the amount of perfusate collected from pulmon-
ary artery (both cavas ligated) per minute. Electrocon-
version (40-50 J) and/or epinephrine (1:50,000-1:100,000)
were used if required [14-16]. Epicardial 2D Echo was
performed using TEE probe for functional assessment at
60 minutes (baseline) and at peak performance, approxi-
mately 90 minutes after initiation of perfusate perfusion in
the two groups with hearts under full workload; and every
30 minutes thereafter. Peak cardiac performance was
defined by the maximum contractile activity observed by
2D Echo. The data at peak performance was used for
comparisons between the two groups.
Enzyme assays and blood chemistry
Quantitative levels of cardiac creatine kinase (CK), aspar-
tate aminotransferase (AST), troponin-I (cTnI), lactate
and gases (pO2/pCO2) were measured intra-operatively
and in SOMAH samples taken at 10 minute, 2-hour and
at end of 5-hour heart storage using Vetscan VS2 or iStat
(Abaxis Ltd, Union City, CA). Inflow (aortic) and outflow
(PA) samples were collected for enzyme assays and
post perfusion assessment of myocardial O2 consump-
tion (MVO2) and lactate levels using Vetscan VS2 or
i-Stat System, at 5 and 90 minutes for enzyme assays,
and at 60 minutes (baseline) and 90 minutes (peak per-
formance) for MVO2 and lactate, after start of perfusate
perfusion with Vetscan or iStat. MVO2 was calculated as
described [20].
Epicardial echocardiography
A trans-esophageal (TEE) probe was used for 2D echo
evaluation of cardiac function intra-operatively and ex vivo
using the Acuson Cypress system (Acuson, Mountain
View, CA) and images were analyzed using Cypress viewer
software provided with the system. Hearts were connected
to SOMAH Device and suspended in a chamber contain-
ing 2 L of perfusate that covered 2/3
rd surface of the heart.
Figure 2 Flow diagram of experimental design. Illustration shows the general experimental design of this study, starting from intraoperative
cardioplegia for cardiac arrest to the end of ex vivo heart reperfusion experiment.
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and 2D Echo acquisition was begun approximately 45–60
minute after perfusion, when good cardiac contractions
were observed, and repeated at 30-minute intervals. Probe
was placed in direct contact with heart and angle of probe
and direction of pulse were adjusted as to obtain short-axis
and long-axis views for calculations of cardiac functional
parameters, and ventricular wall and septal thickness.
Statistical analyses
Equal number of animals (n=5), were assigned to 4°C
and 21°C cardioplegia groups for comparative analysis for
biochemical, hemodynamic and functional measurements
from each group. Statistical comparison for significant
differences between the two groups was performed using
SigmaPlot software. Paired t-test was used for all com-
parisons. P-value of <0.05 was considered significant. All
values are expressed as mean±SEM. Flow diagram of the
experimental design is shown in Figure 2.
The authors had full access to the data and take full
responsibility for its integrity. All authors have read and
agreed to the manuscript as written. The funding agencies
did not play any role in influencing data collection, extrac-
tion and interpretation.
Results
Intraoperative cardioplegia
Cardiac arrest was dependent on the temperature of
cardioplegia and occurred within 10–15 seconds in 4°C
group and 20–25 seconds in the 21°C group, likely be-
cause the hypothermic (4°C) component of cardiac arrest
was deliberately eliminated in the latter.
Gross morphology, heart weights and release of enzymes
during storage
Irrespective of temperature of cardioplegia, all hearts
presented normal gross morphology without any discol-
oration. Hearts were pliable with no signs of hardening
or stiffness. Weights of the hearts during 5-hour storage
in the two groups were not altered between pre and post
storage, demonstrating lack of storage-induced gross edema
(not shown). A time dependent release of cardiac enzymes
was minimally apparent in both groups that were not
significantly different (not shown).
Cardiac tissue HEP levels after arrest and during storage
As shown in Figure 3, concentration of ATP, CP and
total high-energy phosphates (HEP), within 15 minutes
(control) of cardiac arrest were significantly greater in 4°C
as compared to 21°C cardioplegia hearts (P<0.001) pos-
sibly due to the greater consumption of energy in 21°C
group hearts as they required approximately 10 seconds
longer for total arrest. Both groups actively synthesized
CP and ATP during storage, Figure 3B. While the total
concentrations of HEP at the end of storage were signifi-
cantly greater in 4°C hearts (P<0.01), normalization of
values at 5 hour with respect to those at 0 hour dem-
onstrated greater availability of HEP in 21°C hearts than
in 4°C hearts at the end of storage, Figure 3C.
Ex vivo cardiac functional studies
Coronary flow upon reperfusion
Coronary flow through the aorta, upon initial antegrade
perfusion at similar perfusion pressures, was signifi-
cantly greater in 21°C hearts (P<0.05) than the 4°C group
(Table 1). The hearts in both groups demonstrated slow
four chamber contractions immediately upon initiation of
perfusion. Coronary flow decreased initially when system
temperature was raised to 30°C, as the hearts started con-
tracting vigorously. Both pressure and flow increased as
system temperature was raised to 37°C. Coronary flow
was highest in both groups at 37°C (Table 1).
Release of enzymes upon reperfusion
Rate of CK, AST and cTnI release increased in 4°C
hearts during the perfusion period (Figure 4). Both CK
and cTnI release increased significantly with the time of
perfusion, but the AST did not. In contrast, there was a
temporal decrease in release of these three enzymes in
the 21°C hearts during the same period (Figure 4). How-
ever, release of CK and cTnI, but not the AST, was signifi-
cantly greater by the 21°C hearts upon initiation of
perfusion than by the 4°C hearts.
Metabolism in reperfused hearts
Consistent with our previous observations [14-16], there
was a rapid switch in metabolism from anaerobic to
aerobic upon reperfusion in both 4°C and 21°C cardio-
plegia groups, demonstrated by an increase in oxygen
consumption and reversal of lactate ratios at peak perform-
ance, 90 minutes into reperfusion (Figures 5A and B). Oxy-
gen extraction, lactate production and utilization, reached
a steady state in both groups at peak performance that
were not significantly different. However, upon reperfusion,
21°C group hearts demonstrated robust synthesis of HEP
in the working hearts. In contrast, production was attenu-
ated in 4°C hearts and the HEP continued to decline dur-
ing course of the experiment. Ratios (post perfusion/pre
perfusion) of ATP, CP and total HEP were 1.10, 1.97 and
1.17, respectively in 21°C hearts which were significantly
greater (p<0.01) than ratios of 0.47, 0.32 and 0.38 obser-
ved in the 4°C hearts at end of experiment, when post
perfusion biopsies were taken for HEP assays.
Functional revival upon reperfusion
Immediate spontaneous activity of both the atria and
ventricles was apparent upon commencement of reper-
fusion in both groups. With increased temperature, force
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single cardioversion, which also established the normal
electrical activity and electromechanical coupling in
sinus rhythm in both groups. While 4 of the 5 hearts in
21°C cardioplegia group reverted to sinus rhythm with a
single cardioversion and none requiring further inotropic
support, 2 of the 5 hearts in 4°C cardioplegia group
required additionally a single dose of epinephrine to main-
tain optimal function. Interestingly, hearts in both groups
remained pliable throughout the experiment and did not
show any edema at peak performance as indicated by
unaltered thickness of LV and the septum, Table 2. The
comparative data between 4 and 21°C cardioplegia groups
for cardiac functional parameters acquired by 2D Echo
were similar to those observed in vivo (Table 2). Although
hearts that received SOMAH cardioplegia at 21°C ap-
peared to have a better recovery, there were no significant
differences in the functional parameters of the two groups.
Figure 3 High energy phosphate levels in hearts arrested and stored in SOMAH. Cardiac tissue biopsies from left ventricle were obtained for
determination of HEP including ATP and CP levels in 4 and 21°C SOMAH cardioplegia group hearts pre and post 5-hour storage. There was a
temperature of cardioplegia arrest dependent increase in HEP concentrations in the hearts. A: Control; B: 5 hour storage; C: Normalized values
(5 hours with respect to 0 hour). Each bar represents mean±SEM of n= 5 for each group. * Significantly different from 4°C cardioplegia
group hearts.
Table 1 Coronary flow (ml/min) in differential temperature cardioplegia hearts with the rise in system temperature of
SOMAH Device
Heart groups P1 - 21°C F1 - 21°C P2 - 30°C F2 - 30°C P3 - 37°C F3 - 37°C
4°C 40±1 312± 90 44±2 297± 28 53± 4 621±88
21°C 40±1 464± 65* 40±2 348± 64 50± 3 619±34
P1, P2, P3 – Aortic Root Pressures at respective temperatures.
F1, F2, F3 – Coronary Flows at respective temperatures.
*Significant from 4°C.
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We have designed and evaluated SOMAH, a synergistic
extracellular organ storage solution that includes various
energy substrates, metabolic modulators, free radical
scavengers and anti-oxidants, ammonia chelators and
nitric oxide synthase substrates, intra and extracellular
H
+ chelators and physiological concentration of calcium,
components that help prevent edema, ionic imbalance
and energy depletion [12]. SOMAH provides a favorable
environment and cellular support during ex-vivo storage
of hearts, lungs and abdominal organs, and helps attenuate
reperfusion injury upon reanimation [13-16,21]. Promising
Figure 4 Release of creatine kinase and cardiac troponin-I upon reperfusion. CK (A), AST (B) and cTnI (C) levels were determined in perfusate,
5 min and 90 min (peak performance) after start of reperfusion of 4 and 21°C cardioplegia hearts; n=5 for each SOMAH group. *Significant change
from 5 minutes (p <0.05); † Significantly different from 4°C cardioplegia group hearts at similar time point.
Figure 5 Cardiac metabolism in working hearts. Myocardial O2 Consumption (A) and Lactate Ratio (B) upon perfusion of 4 and 21°C cardioplegia
hearts. MVO2 and Lactate ratios were determined from the differences in the respective parameters in the outflow and inflow perfusate samples.
Baseline=60 min after reperfusion, at hemodynamic steady state; 90 min=at peak performance. Each bar represents mean±SEM of n=5 for
each group.
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dertake this study to evaluate SOMAH as a cardioplegia
solution.
Recent results from our laboratory show that extra-
corporeal preservation of hearts for transplant at 21°C
(ambient temperatures) in SOMAH is ideal for the high-
est promotion of synthesis and accumulation of HEP in
heart tissue and preservation of ideal function [13-16].
Based on these results and on the reported advantages
of crystalloid solution [4,22] and tepid temperatures for
cardioplegia [15], the present study was undertaken to eva-
luate whether using crystalloid SOMAH at 21°C instead
of standard temperature of 4°C for cardioplegia could
further improve the quality of hearts preserved at ambient
temperature in SOMAH, and their eventual reanimation
in vitro into optimal function.
Myocardial edema has been reported in hearts arrested
at perfusion pressures of cardioplegia as low as 50 mmHg
[23]. However, in present and past studies we have
consistently used a crystalloid SOMAH cardioplegia
infusion pressure of 100 mmHg irrespective of cardio-
plegia temperature, but edema was not seen in any of
the hearts [14-16]. SOMAH cardioplegia provides all
the advantages of blood cardioplegia, in terms of protec-
tion from cardiac edema and provision of substrates for
energy metabolism, and also provides clear surgical field.
Additionally, provision of physiological concentrations
of calcium in SOMAH solution, also prevents the likeli-
hood of myocardial damage due to ‘calcium paradox’
[6,24]. Furthermore, the disadvantages of blood such as
the presence of leukocytes and platelets, culpable in reper-
fusion injury [25], are also averted. In contrast, the other
crystalloid solutions (Celsior and UWS), when used for
cardioplegia in our recent studies did not prevent loss
of high-energy phosphates in the stored hearts, edema
upon reperfusion and potential high K
+ mediated calcium
overload and stiffness that resulted in non-functioning
hearts [14-16].
In this study, HEP were conserved in 4°C hearts
because of rapid arrest, as a result total concentration of
HEP was also greater in these hearts at the end of stor-
age. In contrast, despite K
+ concentration (20 mM) being
equal in the two groups, the 21°C hearts took longer
for total arrest because of absence of the hypothermic
component, resulting in depletion of HEP. Both groups
synthesized HEP during storage in SOMAH, however, the
functional availability of HEP was greater in 21°C hearts
than the 4°C hearts at the end of 5 hour (Figure 3). Simi-
larly, upon reperfusion, 21°C hearts continued to synthesize
HEP to meet the demands of the working heart, unlike the
4°C hearts. At peak performance the available HEP in 21°C
hearts was significantly greater than 4°C hearts, and contin-
ued to be so during course of the experiments. In contrast,
4°C hearts were unable to synthesize HEP to keep with
the energy demands, thus HEP continued to decrease in
the working hearts. These results are in agreement with
our previous observations that unlike in hearts preserved
in SOMAH at ambient temperatures, exposure to severe
hypothermia leads to attenuation of HEP synthesis upon
reperfusion in these hearts [13].
Antegrade perfusion was significantly lower in the 4°C
heart than in 21°C hearts, and remained diminished,
even at higher perfusion pressures until the system tem-
perature stabilized at 37°C (Table 1). It is plausible that
sudden shock of encountering 4°C cardioplegia by the
normothermic beating heart leads to profound vasocon-
striction that does not resolve during storage and only
does so upon initiation of reperfusion and raising of
temperature to 37°C, and potentially because of active
release of vasodilators nitric oxide and prostacyclins [12].
Increased vasodilation, greater coronary vascular patency
and a favorable metabolic status provides for rapid nour-
ishment and H
+ washout, resulting in robust synthesis of
HEP and swift recovery of function in the 21°C hearts.
These hearts reverted to sinus rhythm with a single car-
dioversion and rapidly attained cardiac and hemodynamic
Table 2 Cardiac functional parameters during surgery and at peak performance upon extracorporeal reperfusion in 4°C
and 21°C SOMAH cardioplegia group hearts
Parameters In vivo 4°C hearts 21°C hearts
LV ant wall thickness (cm) 1.48±0.07 1.55± 0.06 1.51±0.04
Septal thickness (cm) 1.43±0.12 1.61± 0.04 1.49±0.07
Heart rate 98±12 100±10 110± 10
LV systolic pressure (mm Hg) 116± 8 100±20 110± 10
LV diastolic pressure (mm Hg) 68±7 40± 10 55±10
Left atrial pressure (mm Hg) <10 0-5 0-5
Cardiac output 3300±400 2500±300 2640±250
Fractional area change (%) >40 42± 13 51±4
Ejection fraction (%) 65±5 58± 4 66±5
Stroke volume (ml) 29±4 25± 2 24±3
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ing any inotropic support. On the other hand, 4°C hearts
demonstrated strong contraction only when warmed to
37°C, some of the hearts requiring additional electrover-
sion and/or inotropic intervention, albeit ten times less
than that reported in human hearts in vitro [26] to main-
tain cardiac output.
Release of cardiac enzymes was observed in both the
groups upon reperfusion. An important mechanism of
release of enzymes from the cardiomyocyte is by cytosol
leakage during intracellular vesicular trafficking and in-
corporation (such as vesicles harboring glucose transpor-
ters; GLUT) into cell membrane, by a HEP dependent
process, in response to external stimuli like insulin and in-
creased metabolic demands in working hearts [27]. There-
fore, release of cellular enzymes can occur even in absence
of actual damage to the cardiomyocytes (enzyme paradox).
Initial burst of enzyme release in 21°C cardioplegia group
upon initiation of reperfusion likely resulted from greater
availability of HEP at the end of storage for vesicular
transport as the metabolic demands were ramped up with
increase in system temperature and cardiac contractility
(Figure 3). However, upon reaching metabolic steady state
any further release of enzyme was temporally attenuated.
In contrast, in the 4°C hearts, the rate of release of en-
zymes increased with time as more HEP became available
for these functions. Even though the present data does not
differentiate between progressions of enzyme release and
needs further investigation, the fact, that the cardiac
functional parameters in both groups were similar and ap-
proach the physiological values observed in vivo (Table 2)
indicate that the releases of enzymes by the SOMAH
hearts is a marker of metabolism rather than tissue
injury and hence these hearts would perform well upon
transplant.
Certain limitations were inherent to this study. While
the present findings indicate a certain advantage of using
SOMAH at 21°C for clinical cardioplegia either intraoper-
atively or during heart procurement for transplantation, in
the present preliminary study we have performed only a
modest number of experiments in each group and used
2D echocardiography for the functional evaluation of
reperfused hearts. While this provided convincing evi-
dence in favor of 21°C cardioplegia, further studies using
Pressure-Volume loops acquisition and analysis for precise
determination and interpretation of the significant bio-
physiological effects of SOMAH on extracorporeal cardiac
reperfusion under varying conditions, are required.
Conclusion
Efficient HEP metabolism, decreased rate of enzyme
release, and diminished requirement for stimulatory inter-
ventions suggest that use of SOMAH for cardioplegia and
storage at 21°C optimally protects the heart function and
thus may positively influence post operative outcomes
upon transplant. Extrapolating ex vivo 5 hour preservation
as analogous to cross clamp time, use of SOMAH cardio-
plegia at ambient temperatures during open heart surgery,
where the cross clamp times generally do not exceed
3 hours (average 60–90 minutes); where the hearts are
periodically flushed with 500 ml of fresh cardioplegia
every 20 to 30 minutes during cross clamp, may signifi-
cantly improve post surgical outcomes. However, further
studies are needed to translate this inferential hypothesis
into a clinical reality.
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